The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials
Abstract
Aims: To evaluate the effects of different sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on the risk of urinary tract infections ( UTIs ) and genital infections in patients with type 2 diabetes mellitus ( T2DM ). Materials and methods: We systematically searched PubMed , Embase, CENTRAL , and ClinicalTrials.gov from inception to October 9, 2016 to identify randomized controlled trials ( RCTs ) reporting the occurrence of UTIs and genital infections in patients with T2DM treated with SGLT2 inhibitors. Pairwise and network meta‐analyses were performed to calculate odds ratios ( ORs ) and 95% confidence intervals ( CIs ). Meta‐regression was performed to assess explanatory factors that might influence effect size. Results: A total of 52 RCTs involving 36 689 patients were eligible for our meta‐analysis. Canagliflozin, dapagliflozin and empagliflozin were associated with a higher risk of genital infections than placebo, with ORs ranging from 3.21 (95% CI 2.08‐4.93) for dapagliflozin 2.5 mg to 5.23 (95% CI 3.86‐7.09) for canagliflozin 300 mg. Only dapagliflozin 10 mg led to significantly more UTIs than placebo. The increased risk of UTIs and genital infections seemed to have a dose–response relationship for dapagliflozin only. No factors that had a significant modification effect on these infectious events were detected in meta‐regression analysis. Conclusions: The present study found that canagliflozin, dapagliflozin and empagliflozin were associated with a significantly higher risk of genital infections compared with placebo and other active treatments. Only dapagliflozin had a dose–response relationship with UTIs and genital infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Grundy, S. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,563
Immune dysfunction in patients with diabetes mellitus (DM)
Geerlings, S. (1999) · FEMS Immunology and Medical Microbiology · doi:10.1016/s0928-8244(99)00142-x · Cited by 1,272
Research works printed but not linked: 2
- Higgins JPT, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 510 (updated March 2011)
- 10.1111/j.1574-695X.1999.tb01397.x · doi:10.1111/j.1574-695x.1999.tb01397.x · Paper page
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00536-5 · Cited by 581
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Metadata
- Authors
- Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-12-19
- Volume
- 19
- Issue
- 3
- Pages
- 348-355
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2551376414
- Cited by
- 253
- References
- 53
- FWCI
- 14.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/dom.12825
- The paper
- Li, D., Wang, T., Shen, S., Fang, Z., Dong, Y., & Tang, H. (2017). Urinary tract and genital infections in patients with type 2 diabetes treated with sodium‐glucose co‐transporter 2 inhibitors: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12825
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.